Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin vs Ciprofloxacin in Complicated UTI
NCT00258089Phase 3
Key facts
- Status
- Completed
- Start
- Jun 1993
- Sponsor
- Johnson & Johnson
- Modality
- Small Molecules
- Drugs
- levofloxacin
- Conditions
- complicated urinary tract infection (cUTI)
01
Overview
Phase 3, randomised, double-blind trial of levofloxacin in complicated urinary tract infection (cUTI) (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Clinical Response and Microbiological Response. Started Jun 1993; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Levofloxacin
Levofloxacin 250 mg QD + Placebo
Ciprofloxacin
Ciprofloxacin 500 mg BID + Placebo
03
Who it enrols
Adults with complicated urinary tract infections capable of taking oral medication. Excludes patients requiring IV therapy, with complete urinary obstruction, prostate inflammation, or pregnancy.
04
Endpoints
Primary
Clinical Response
Microbiological Response
Secondary
Overall Clinical Response
Incidence of Adverse Events
Change in Clinical Laboratory Tests
Beyond the preview
Go deeper on NCT00258089.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258089.